Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Sees Large Decrease in Short Interest

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 128,849 shares, a decrease of 36.8% from the July 15th total of 203,982 shares. Based on an average daily volume of 43,492 shares, the short-interest ratio is currently 3.0 days. Currently, 0.6% of the company’s stock are short sold.

Qualigen Therapeutics Trading Up 4.9%

AIXC opened at $0.71 on Tuesday. Qualigen Therapeutics has a twelve month low of $0.59 and a twelve month high of $8.81. The firm has a market cap of $14.37 million, a price-to-earnings ratio of -0.13 and a beta of 0.53. The company has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $1.20.

Qualigen Therapeutics (NASDAQ:AIXC) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.21) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Qualigen Therapeutics has an average rating of “Sell”.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.